BIOCYTOGEN-B Shares Surge Over 14% Following Strategic Global Partnership Announcement for BsADC Development

Shares of BIOCYTOGEN-B (02315) have surged more than 14% in today's trading session.

At the time of writing, the stock is up 13.94% to HK$53.55, with a trading turnover of HK$51.74 million.

Catalyst for the Move

The significant price movement follows a recent company announcement regarding a major strategic partnership.

The firm and Whitehawk Therapeutics, Inc. have jointly announced the signing of a global strategic collaboration agreement.

This agreement encompasses several bispecific antibody-drug conjugate (BsADC) research and development projects.

The partnership aims to establish a broader strategic alliance to advance a diversified pipeline of next-generation therapeutic products.

A key objective is to accelerate the development of innovative treatments for cancer and other serious diseases.

Terms of the Agreement

Under the terms of the agreement, BIOCYTOGEN-B will provide up to five fully human bispecific antibodies derived from its proprietary RenLite® platform.

Whitehawk will evaluate these antibodies using its own ADC linker-payload platform technology.

Following this evaluation, Whitehawk will have the option to select the resulting BsADC candidate molecules for inclusion in its development pipeline.

Platform Advantages

The RenLite® platform employs a common light chain design, which facilitates the discovery, screening, and optimization of fully human bispecific antibodies against various target combinations.

This design also effectively reduces the risk of heavy and light chain mispairing, providing a robust molecular foundation for subsequent BsADC development.

Strategic Rationale

By integrating the complementary strengths of BIOCYTOGEN-B and Whitehawk, the collaboration is designed to identify BsADC candidate molecules with differentiated targeting mechanisms and significant therapeutic potential.